FDA Asks: How Do You Paper-Trail Your Medicated Moo Juice?
Published Date: 2/25/2026
Notice
Summary
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Licensed Feedmills: Large recordkeeping burden
If you run a registered, licensed commercial medicated feed mill, you must establish, maintain, and retain records under 21 CFR part 225 documenting receipts, inventory of drug components, batch production, laboratory assay results, labels, and product distribution. FDA estimates for these registered licensed commercial feed mills a total of 2,241,792 annual responses and 683,747 total annual recordkeeping hours (average 18.3 minutes or 0.305 hours per response).
Non‑licensed Mixer/Feeders: recordkeeping hours
If you run a nonregistered, non‑licensed mixer/feeder that produces medicated feeds, you must keep records under 21 CFR part 225 for components, lab controls, labeling, production, and distribution. FDA estimates 3,400 such recordkeepers producing 309,400 total annual records and requiring 420,784 total annual hours (average 1.36 hours per record).
Non‑licensed Commercial Feedmills: recordkeeping needs
If you operate a nonregistered, non‑licensed commercial feed mill that manufactures medicated feeds, you must keep records under 21 CFR part 225 for components, laboratory controls, packaging and labeling, production, and distribution. FDA estimates 1,658 recordkeepers with 150,878 total annual records and 217,265 total annual hours (average 1.44 hours per record).
Type A Medicated Article Makers: hourly burden
If you manufacture Type A medicated articles under 21 CFR part 226, you must keep records for premix components, laboratory controls, packaging, master formulas, batch production, distribution, and complaint files. FDA estimates 65 respondents generating 89,050 annual responses with about 89,050 total annual hours (approximately 1 hour per response).
FDA lowers estimated paperwork burden
FDA reports it adjusted its inventory and reduced the estimated number of medicated‑feed recordkeepers by 2,722, resulting in a decrease of 13,731,017 records and a decrease of 913,153 total annual recordkeeping hours. This change updates the compliance burden estimate for affected manufacturers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-03771 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Retailer Training Programs
The FDA is asking for public feedback on their plan to keep collecting info about tobacco retailer training programs. These programs help stores teach employees the rules about selling tobacco safely and legally. If approved, this will continue without extra costs but keep the training standards clear and up-to-date. Comments are due by March 27, 2026, so retailers and the public can weigh in!
Next: 2026-03773 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing.
The FDA wants to hear from companies that make biological products and human tissues about how they report mistakes during manufacturing. They’re asking for feedback on updating the forms and rules to keep things clear and safe. If you’re involved in making these products, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just a chance to help improve the process!